Back to results
US 2025/0101400 A1Published application
Novel crispr enzymes and systems
AssigneesThe Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
InventorsFeng Zhang, Ian Slaymaker, Soumya Kannan, Jonathan Gootenberg, Omar Abudayyeh
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
Claims29
A non-naturally occurring or engineered composition comprising:
- (a) a Type VI Cas protein having at least 90% sequence identity to SEQ ID NO. 274;
- and
- (b) a guide sequence capable of forming of complex with the Cas protein and directing the complex to bind to a target sequence.
A non-naturally occurring or engineered composition comprising:
- (a) a Type VI Cas protein having at least 90% sequence identity to SEQ ID NO. 274;
- (b) a nucleotide deaminase fused or linked to the Cas protein and
- (c) a guide sequence capable of forming of complex with the Cas protein and directing the complex to bind to a target sequence
- (d) wherein the Cas protein is catalytically inactive and comprises an N-terminal truncation, a C-terminal truncation, or both.
1 more element
Dependencies are inferred from the claim text.